Tyme Technologies (TYME) versus Lipocine (LPCN) Head to Head Comparison

Lipocine (NASDAQ: LPCN) and Tyme Technologies (NASDAQ:TYME) are both small-cap bio therapeutic drugs companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Lipocine and Tyme Technologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine 0 1 3 0 2.75
Tyme Technologies 0 0 3 0 3.00

Lipocine presently has a consensus target price of $13.50, indicating a potential upside of 892.65%. Tyme Technologies has a consensus target price of $7.50, indicating a potential upside of 23.15%. Given Lipocine’s higher probable upside, equities research analysts clearly believe Lipocine is more favorable than Tyme Technologies.

Earnings & Valuation

This table compares Lipocine and Tyme Technologies’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lipocine N/A N/A -$18.97 million ($0.96) -1.42
Tyme Technologies N/A N/A -$15.20 million ($0.16) -38.06

Tyme Technologies is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Lipocine has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500. Comparatively, Tyme Technologies has a beta of -42.35, indicating that its share price is 4,335% less volatile than the S&P 500.

Institutional and Insider Ownership

22.1% of Lipocine shares are held by institutional investors. Comparatively, 2.4% of Tyme Technologies shares are held by institutional investors. 11.3% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Lipocine and Tyme Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lipocine N/A -74.63% -68.41%
Tyme Technologies N/A -196.81% -136.25%

Summary

Lipocine beats Tyme Technologies on 7 of the 10 factors compared between the two stocks.

About Lipocine

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

About Tyme Technologies

Tyme Technologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system. The Company’s lead clinical program, SM-88, is a first-in-class combination therapy in Phase II development for prostate cancer, and it is preparing to initiate an additional Phase II clinical trial for pancreatic cancer. The Company provides a novel compound for physicians to use in a treatment regimen for patients fighting six major cancers including breast, lung, prostate, gastric, esophageal and pancreatic cancers.

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply